Bristol-Myers Squibb (NYSE: BMY) shocked everybody when it announced its $74 billion acquisition of Celgene (NASDAQ: CELG) earlier this year. Not everyone was happy, with the merger drawing the ire of some of the biggest institutional investors. Is this deal as bad as they fear?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,